Cargando…
Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
Autores principales: | Huang, Tang-Hsiu, Kuo, Chin-Wei, Chen, Chian-Wei, Tseng, Yau-Lin, Wu, Chao-Liang, Lin, Sheng-Hsiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186065/ https://www.ncbi.nlm.nih.gov/pubmed/34103038 http://dx.doi.org/10.1186/s12890-021-01559-7 |
Ejemplares similares
-
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
por: Huang, Tang-Hsiu, et al.
Publicado: (2021) -
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021) -
Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019) -
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018) -
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)